Early identification of Epstein‐Barr virus‐associated post‐transplantation lymphoproliferative disease

Cliona M. Rooney, Susan K. Loftin, Martha S. Holladay, Malcolm K. Brenner, Robert A. Krance, Helene E. Heslop

Research output: Contribution to journalArticlepeer-review

203 Scopus citations


Epstein-Barr virus-associated lymphoproliferative disease (EBV-LPD) is a common, usually fatal, complication developing after transplantation of bone marrow from HLA-mismatched or HLA-matched unrelated donors. Prompted by recent reports of successful treatment of EBHV-LPD, we investigated methods which could result in early identification of patients at high risk for this disorder, thus improving the likelihood of successful therapeutic interventions. Both the outgrowth of transformed B lymphocytes ex vivo (100% correlation) and the detection of EBV DNA by a PCR method (80% correlation) showed statistically significant association with the histopathological diagnosis of EBV-LPD. Because these abnormalities can be detected prior to the onset of clinical disease, it should now be possible to use a combination of the methods described here to identify patients at high risk of developing EBV-LPD, thus enabling early therapeutic intervention.

Original languageEnglish (US)
Pages (from-to)98-103
Number of pages6
JournalBritish Journal of Haematology
Issue number1
StatePublished - Jan 1995


  • BMT
  • diagnosis
  • Epstein-Barr virus
  • lymphoproliferation
  • treatment

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Early identification of Epstein‐Barr virus‐associated post‐transplantation lymphoproliferative disease'. Together they form a unique fingerprint.

Cite this